More importantly, ADQ treatment also significantly delayed TAM co-injection-induced mammary tumor growth, while CXCL1 overexpression in the co-injected TAMs partially abrogated that effect (Fig. 6a–c, Additional file 1: Fig. 3). Here, CXCL1 is linked to breast cancer.